01 — Discuss
Share your intended application, target market, product format, proposed dose and development priorities.
FORMULATION SUPPORT
Serious science. Practical formulation support.
veMico supports nutrition brands, ingredient partners and contract manufacturers in incorporating VMK223 into finished products, providing scientific evidence, technical expertise and commercial support from initial formulation through to supply.
PARTNER PROCESS
From first conversation to commercial supply.
02 — Evaluate
Review available ingredient specifications, published research and technical documentation for suitability.
03 — Develop
Work with your own formulation and manufacturing teams, supported by veMico’s guidance on compatibility, processing and ingredient incorporation.
04 — Supply
Discuss order volumes, relevant documents, lead times and commercial supply arrangements.
COMMERCIAL PARTNERSHIPS
Commercial adoption of VMK223.
Selentra HP — Calroy Health Sciences
VMK223 has been selected by Calroy Health Sciences for Selentra HP, a women’s health supplement launched in the United States in October 2026. The formulation provides 500 mg VMK223 per daily serving, illustrating its commercial application in women’s midlife nutrition.
View Selentra HP ↗
INGREDIENT INFORMATION
Information to support your decision.
Technical documentation
Available ingredient specifications, composition, analytical, manufacturing and quality information.
Formulation guidance
Discussion of intended dose, stability data, processing conditions and compatibility with proposed formats.
Scientific evidence
Published standalone human trials, relevant mechanistic studies and appropriately identified additional research.
Regulatory & commercial information
Available safety and regulatory documentation, supply requirements and order terms, subject to target market and partner needs.
Ready to explore VMK223 for your next formulation?
Discuss your concept, technical requirements and commercial priorities with veMico.
Request Technical Information →